PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 77 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.36 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $985,824 | -12.4% | 95,065 | +21.0% | 0.00% | – |
Q2 2023 | $1,125,366 | +103.8% | 78,587 | +1.6% | 0.00% | – |
Q1 2023 | $552,187 | -38.4% | 77,337 | -3.3% | 0.00% | – |
Q4 2022 | $896,870 | +10.2% | 79,935 | +8.7% | 0.00% | – |
Q3 2022 | $814,000 | +49.6% | 73,520 | +14.2% | 0.00% | – |
Q2 2022 | $544,000 | -34.8% | 64,357 | +5.0% | 0.00% | – |
Q1 2022 | $834,000 | -28.6% | 61,288 | +3.3% | 0.00% | – |
Q4 2021 | $1,168,000 | -37.4% | 59,340 | +2.1% | 0.00% | – |
Q3 2021 | $1,867,000 | +8.5% | 58,142 | +14.4% | 0.00% | – |
Q2 2021 | $1,720,000 | +11.1% | 50,819 | +23.3% | 0.00% | – |
Q1 2021 | $1,548,000 | +6.7% | 41,222 | -5.6% | 0.00% | – |
Q4 2020 | $1,451,000 | -9.9% | 43,668 | -0.6% | 0.00% | – |
Q3 2020 | $1,610,000 | +10.9% | 43,932 | -0.4% | 0.00% | – |
Q2 2020 | $1,452,000 | +47.1% | 44,115 | +15.4% | 0.00% | – |
Q1 2020 | $987,000 | +27.8% | 38,233 | +54.2% | 0.00% | – |
Q4 2019 | $772,000 | – | 24,794 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |